This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rubin, M. A. Articles by Chinnaiyan, A. M. Search for Related Content PubMed PubMed Citation Articles by Rubin, M. A. Articles by Chinnaiyan, A. M.

Overexpression, Amplification, and Androgen Regulation of TPD52 in Prostate Cancer

¹ Department of Pathology, Brigham and Women’s Hospital, Boston, Massachusetts; ² Harvard Medical School, Boston, Massachusetts; Departments of ³ Pathology, ⁴ Urology, and ⁵ Internal Medicine and ⁶ Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, Michigan; ⁷ Dana-Farber Cancer Institute, Boston, Massachusetts; ⁸ Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California; ⁹ Department of Urology, University Hospital of Ulm, Ulm, Germany; and ¹⁰ Molecular Oncology Laboratory, Oncology Research Unit, The Children’s Hospital at Westmead, New South Wales, Australia

Gains in the long arm of chromosome 8 (8q) are believed to be associated with poor outcome and the development of hormone-refractory prostate cancer. Based on a meta-analysis of gene expression microarray data from multiple prostate cancer studies (D. R. Rhodes et al., Cancer Res 2002;62:4427–33), a candidate oncogene, Tumor Protein D52 (TPD52), was identified in the 8q21 amplicon. TPD52 is a coiled-coil motif-bearing protein, potentially involved in vesicle trafficking. Both mRNA and protein levels of TPD52 were highly elevated in prostate cancer tissues. Array comparative genomic hybridization and amplification analysis using single nucleotide polymorphism arrays demonstrated increased DNA copy number in the region encompassing TPD52. Fluorescence in situ hybridization on tissue microarrays confirmed TPD52 amplification in prostate cancer epithelia. Furthermore, our studies suggest that TPD52 protein levels may be regulated by androgens, consistent with the presence of androgen response elements in the upstream promoter of TPD52. In summary, these findings suggest that dysregulation of TPD52 by genomic amplification and androgen induction may play a role in prostate cancer progression.

This article has been cited by other articles:

				M. Shehata, I. Bieche, R. Boutros, J. Weidenhofer, S. Fanayan, L. Spalding, N. Zeps, K. Byth, R. K. Bright, R. Lidereau, et al. Nonredundant Functions for Tumor Protein D52-Like Proteins Support Specific Targeting of TPD52 Clin. Cancer Res., August 15, 2008; 14(16): 5050 - 5060. [Abstract] [Full Text] [PDF]

				B. S. Knudsen, A. N. Allen, D. F. McLerran, R. L. Vessella, J. Karademos, J. E. Davies, B. Maqsodi, G. K. McMaster, and A. R. Kristal Evaluation of the Branched-Chain DNA Assay for Measurement of RNA in Formalin-Fixed Tissues J. Mol. Diagn., March 1, 2008; 10(2): 169 - 176. [Abstract] [Full Text] [PDF]

				S. R. Setlur, T. E. Royce, A. Sboner, J.-M. Mosquera, F. Demichelis, M. D. Hofer, K. D. Mertz, M. Gerstein, and M. A. Rubin Integrative Microarray Analysis of Pathways Dysregulated in Metastatic Prostate Cancer Cancer Res., November 1, 2007; 67(21): 10296 - 10303. [Abstract] [Full Text] [PDF]

				J. H. Kim, S. M. Dhanasekaran, R. Mehra, S. A. Tomlins, W. Gu, J. Yu, C. Kumar-Sinha, X. Cao, A. Dash, L. Wang, et al. Integrative Analysis of Genomic Aberrations Associated with Prostate Cancer Progression Cancer Res., September 1, 2007; 67(17): 8229 - 8239. [Abstract] [Full Text] [PDF]

				J. D. Lewis, L. A. Payton, J. G. Whitford, J. A. Byrne, D. I. Smith, L. Yang, and R. K. Bright Induction of Tumorigenesis and Metastasis by the Murine Orthologue of Tumor Protein D52 Mol. Cancer Res., February 1, 2007; 5(2): 133 - 144. [Abstract] [Full Text] [PDF]

				S. Perner, F. Demichelis, R. Beroukhim, F. H. Schmidt, J.-M. Mosquera, S. Setlur, J. Tchinda, S. A. Tomlins, M. D. Hofer, K. G. Pienta, et al. TMPRSS2:ERG Fusion-Associated Deletions Provide Insight into the Heterogeneity of Prostate Cancer. Cancer Res., September 1, 2006; 66(17): 8337 - 8341. [Abstract] [Full Text] [PDF]

				P. J.M. Hendriksen, N. F.J. Dits, K. Kokame, A. Veldhoven, W. M. van Weerden, C. H. Bangma, J. Trapman, and G. Jenster Evolution of the Androgen Receptor Pathway during Progression of Prostate Cancer. Cancer Res., May 15, 2006; 66(10): 5012 - 5020. [Abstract] [Full Text] [PDF]

				C. Chen, X. Sun, P. Guo, X.-Y. Dong, P. Sethi, X. Cheng, J. Zhou, J. Ling, J. W. Simons, J. B. Lingrel, et al. Human Kruppel-like Factor 5 Is a Target of the E3 Ubiquitin Ligase WWP1 for Proteolysis in Epithelial Cells J. Biol. Chem., December 16, 2005; 280(50): 41553 - 41561. [Abstract] [Full Text] [PDF]

				E. Tiacci, P.-L. Orvietani, B. Bigerna, A. Pucciarini, G. L. Corthals, V. Pettirossi, M. P. Martelli, A. Liso, R. Benedetti, R. Pacini, et al. Tumor protein D52 (TPD52): a novel B-cell/plasma-cell molecule with unique expression pattern and Ca2+-dependent association with annexin VI Blood, April 1, 2005; 105(7): 2812 - 2820. [Abstract] [Full Text] [PDF]